P站视频

Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007 Feb 15;109(4):713-717.

Elliott MA. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol. 2006;19(3):571-593.

Faderl S, Kantarjian H. Myelodysplastic syndromes. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1988-1996.

Foran JM, Sekeres MA. Myelodysplastic Syndromes. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2235-2259.

Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20;29(18):2521-7. Epub 2011 May 16.

Germing U, Gattermann, Strupp C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leukemia Research. 2000;24:983-992.

Germing U, Strupp C, Knipp S, et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 2007 Jul;92(7):974-977.

Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER website, April 2013.

Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009 May;14(5):489-496.

Nguyen PL, Hanson CA. Chronic Myelomonocytic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndromes. In: Steensma DP, ed. Myelodysplastic Syndromes: Pathobiology and Clinical Management, 2nd ed. New York, NY: Informa Healthcare, 2009: 285-310.

NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. V.2.2014. Accessed at: www.nccn.org on August 14, 2012.

PDQ database. Myelodysplastic/Myeloproliferative Diseases Treatment. 11/19/2013. National Cancer Institute. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/mds-mpd/HealthProfessional on December 6, 2013.

Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10;27(23):3842-3848.